An interventional study of Femtosecond Laser Capsulotomy - Small Size (4.6 mm) and Femtosecond Laser Capsulotomy - Large Size (5.6 mm) in Cataract Surgery, Intraocular Lens Position and Refractive Outcomes After Cataract Surgery, sponsored by Twin Cities Eye Consultants. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Twin Cities Eye Consultants · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.
Among the 456 studies in Cataract with a site in United States, this one is the 281st largest by enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 150 with no phase, and was the 453rd registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eric Rosenberg · Sites in United States
Ages 18–90
The Eye Institute of West Florida · Sites in United States
Ages 40+
Gainesville Eye Associates · Sites in United States
Ages 18+
Laser Defined Vision · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
456 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 59 · Phase 4 86
First in 1987; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 100 across the 322 interventional studies, 61 across the 128 observational. Of the 365 that completed or were terminated, 177 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
239 of 456 have an industry lead sponsor. The 10 most frequent:
Twin Cities Eye Consultants is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Twin Cities Eye Consultants has 1 study filed under Cataract — fewer than ten, so there is no comparison to draw.
21 of the studies in Cataract with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07898917Gainesville Eye AssociatesPureSee/Odyssey Mix-and-Match IOL | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07260695Center For SightOdyssey Evaluation in Post LASIK Patients | 2026-12-18 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 456 studies in Cataract with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether the size of the opening made during laser-assisted cataract surgery affects where the artificial lens sits in the eye and the glasses prescription after surgery.
This study includes adults aged 40 years and older who are scheduled to have cataract surgery in both eyes. Cataract surgery removes the cloudy natural lens of the eye and replaces it with a clear artificial lens, called an intraocular lens.
The main questions this study aims to answer are:
Each participant will receive two different capsulotomy sizes, one in each eye. The size (big or small) used in each eye is chosen by chance. Both sizes are safe and commonly used during cataract surgery. All surgeries use a laser system that allows the opening to be made very precisely.
Participants will:
Participants will receive the same type of lens implant and standard follow-up care whether or not they join the study. There is no direct benefit from taking part. The information learned may help doctors improve planning and accuracy for future cataract surgeries.
Accurate prediction of effective lens position (ELP) is a critical factor in achieving optimal refractive outcomes following cataract surgery. Even small variations in the postoperative position of an intraocular lens (IOL) can influence refractive accuracy and patient satisfaction. One surgical factor that may contribute to ELP variability is the size of the anterior capsulotomy, which affects IOL centration, capsular overlap, and long-term stability within the capsular bag.
The PRECISE study is a prospective, randomized, within-subject clinical investigation designed to evaluate the effect of capsulotomy size on postoperative effective lens position and refractive outcomes in patients undergoing femtosecond laser-assisted cataract surgery. By using a paired-eye design, each participant serves as their own control, thereby minimizing inter-individual variability related to ocular anatomy, wound healing, and biometric differences.
All surgical procedures are performed using the LENSAR ALLY® femtosecond laser system, which allows for highly precise, reproducible, and well-centered capsulotomies. Two different capsulotomy sizes are used in this study, 4.6 mm and 5.6 mm, both of which fall within accepted standards of care and are commonly employed in routine cataract surgery. Capsulotomy size assignment is randomized between eyes. Aside from capsulotomy size, all other aspects of the surgical procedure, including IOL model and surgical technique, remain consistent with standard clinical practice.
Participants undergo comprehensive preoperative evaluation, including visual acuity testing, ocular biometry, optical coherence tomography imaging, and slit-lamp examination. These assessments are repeated at a final postoperative study visit approximately 12 weeks after the second eye surgery to evaluate lens position and refractive status. Standard postoperative follow-up visits required for routine cataract care are conducted separately and are not altered by study participation.
The study focuses on detecting subtle differences in effective lens position and refractive outcomes that may be associated with capsulotomy size. Any anticipated differences in ELP are expected to be small and unlikely to result in clinically noticeable visual changes for participants. However, identifying consistent trends may provide insight into the role of capsulotomy geometry in IOL behavior and help refine IOL power calculations, surgical planning, and refractive predictability in future cataract surgery patients.
No experimental devices or medications are used in this study. All participants receive standard monofocal intraocular lenses and routine perioperative care. The risks associated with participation are consistent with those of standard cataract surgery, and no additional study-specific risks are anticipated.
Overall, this study aims to contribute to a better understanding of the relationship between femtosecond laser capsulotomy size and postoperative lens position, with the long-term goal of improving precision and outcomes in cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive femtosecond laser-assisted cataract surgery with a smaller capsulotomy size (4.6 mm) created using the LENSAR ALLY laser system. This capsulotomy size is within standard clinical practice and is randomly assigned to one eye.
Procedure: Femtosecond Laser Capsulotomy - Small Size (4.6 mm)
Participants will receive femtosecond laser-assisted cataract surgery with a larger capsulotomy size (5.6 mm) created using the LENSAR ALLY laser system. This capsulotomy size is within standard clinical practice and is randomly assigned to the contralateral eye.
Procedure: Femtosecond Laser Capsulotomy - Large Size (5.6 mm)
Femtosecond laser-assisted cataract surgery in which a smaller capsulotomy (4.6 mm) is created using the LENSAR ALLY laser system. The capsulotomy size is within standard clinical practice and is randomly assigned to one eye. All other aspects of cataract surgery, including intraocular lens implantation and postoperative care, follow routine clinical standards.
Also known as: LENSAR ALLY Laser Capsulotomy (Small), 4.6 mm
Femtosecond laser-assisted cataract surgery in which a larger capsulotomy (5.6 mm) is created using the LENSAR ALLY laser system. The capsulotomy size is within standard clinical practice and is randomly assigned to the contralateral eye. All other aspects of cataract surgery, including intraocular lens implantation and postoperative care, follow routine clinical standards.
Also known as: LENSAR ALLY Laser Capsulotomy (Large), 5.6 mm
Anterior Chamber Depth (ACD)
Difference in anterior chamber depth (ACD) between eyes receiving a 4.6 mm femtosecond laser capsulotomy and eyes receiving a 5.6 mm femtosecond laser capsulotomy. ACD will be measured using standard optical biometry to assess the final position of the implanted monofocal intraocular lens.
Time frame: 12 weeks after second eye surgery
Refractive Accuracy (MRSE vs Target Refraction)
Difference between the manifest refraction spherical equivalent (MRSE) and the intended target refraction for each eye following cataract surgery, comparing eyes with different capsulotomy sizes.
Time frame: 12 weeks after second eye surgery
Residual Refractive Error Distribution
Percentage of eyes within ±0.25 D, ±0.50 D, ±0.75 D, and ±1.00 D of target refraction following cataract surgery, comparing eyes receiving a 4.6 mm versus a 5.6 mm capsulotomy.
Time frame: 12 weeks after second eye surgery
Distance Visual Acuity Outcomes
Uncorrected distance visual acuity (UDVA) and best-corrected distance visual acuity (BCVA) following cataract surgery, reported as the percentage of eyes achieving visual acuity thresholds of 20/20, 20/25, 20/32, 20/40, and 20/60 or worse, comparing eyes with different capsulotomy sizes.
Time frame: 12 weeks after second eye surgery
Plan to share: No
Ran from Oct 2025 to primary completion in Mar 2026, 4 months.
Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 4 months is below that.
Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Twin Cities Eye Consultants